Expansion
BioMarin licenses Fabry disease ERT candidate in up to $475M deal with GC Biopharma and Hanmi
Key Facts
Signal Type
Expansion
Industry
Biotech
Companies
BioMarin, GC Biopharma, Hanmi Pharm, Amicus Therapeutics, Sanofi
Date
BioMarin entered a licensing agreement with GC Biopharma and Hanmi Pharm to acquire worldwide rights (excluding South Korea) to HM15421/GC1134A, a phase 1/2 long-acting enzyme replacement therapy (ERT) for Fabry disease. The deal includes $70 million upfront and up to $405 million in development and commercial milestones, plus tiered royalties on net sales. The candidate is designed for subcutaneous injection once monthly, compared to current approved ERTs that require intravenous infusion every two weeks.
BioMarin’s Fabry disease team, including clinical development, regulatory, and commercial operations, will manage the new ERT program. The company already markets Galafold, an oral therapy generating $521.7M in 2025 from the Amicus acquisition, but Galafold is limited to patients with certain genetic mutations. The ERT could serve a broader patient population, increasing the addressable market. Competitors Sanofi, Chiesi, and Takeda have approved ERTs, while Amicus (now part of BioMarin) and other players remain relevant.
BioMarin’s pipeline expansion strengthens its position in the Fabry disease market, currently dominated by Sanofi’s Fabrazyme and Chiesi’s Elfabrio. The once-monthly subcutaneous profile could differentiate HM15421/GC1134A and capture patient preference over biweekly IV infusions. Key impacts include:
Monitor early phase 1/2 data on safety and efficacy, particularly the pharmacokinetic profile at three dose levels and kidney function outcomes over the 48-week study period. The enrollment pace in U.S. sites will signal trial execution quality. Additionally, watch for any regulatory alignment discussions or expansion into new geographies as BioMarin advances the candidate toward pivotal trials.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
